Abiraterone acetate - Druggability Technologies

Drug Profile

Abiraterone acetate - Druggability Technologies

Alternative Names: DRGT 45

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Druggability Technologies
  • Class Androstenols; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 04 Jan 2017 Chemical structure information added
  • 09 Dec 2016 Druggability Technologies plans a pivotal trial for Prostate cancer
  • 26 Jul 2016 DRGT 45 is available for licensing as of 26 Jul 2016. http://www.drgtco.com/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top